TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease

被引：5
|
作者：
Salloway, Stephen [1 ,2 ,3 ]
Lee, Elly [4 ]
Papka, Michelle [5 ]
Pain, Andrew [6 ]
Oru, Ena [6 ]
Ferguson, Margaret B. [6 ]
Wang, Hong [6 ]
Case, Michael [6 ]
Lu, Ming [6 ]
Collins, Emily C. [6 ]
Brooks, Dawn A. [6 ]
Sims, John [6 ]
机构：
[1] Brown Univ, Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA
[2] Brown Univ, Alpert Med Sch, Dept Psychiat, Providence, RI 02912 USA
[3] Butler Hosp, Providence, RI 02906 USA
[4] Irvine Clin Res, Irvine, CA USA
[5] Cognit & Res Ctr New Jersey LLC, Springfield, NJ USA
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
BJPSYCH OPEN | 2023年 / 9卷
关键词：
D O I：
10.1192/bjo.2023.227
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 17 条
  • [1] TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease
    Salloway, Stephen
    Lee, Elly
    Papka, Michelle
    Pain, Andrew
    Oru, Ena
    Ferguson, Margaret
    Wang, Hong
    Case, Michael
    Lu, Ming
    Collins, Emily
    Brooks, Dawn
    Sims, John
    NEUROLOGY, 2023, 100 (17)
  • [2] TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
    Salloway, Stephen
    Lee, Elly
    Papka, Michelle
    Pain, Andrew
    Oru, Ena
    Ferguson, Margaret B.
    Wang, Hong
    Case, Michael
    Lu, Ming
    Collins, Emily C.
    Brooks, Dawn A.
    Sims, John
    BJPSYCH OPEN, 2023, 9 : S67 - S67
  • [3] Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
    Sims, John R.
    Zimmer, Jennifer A.
    Evans, Cynthia D.
    Lu, Ming
    Ardayfio, Paul
    Sparks, JonDavid
    Wessels, Alette M.
    Shcherbinin, Sergey
    Wang, Hong
    Nery, Emel Serap Monkul
    Collins, Emily C.
    Solomon, Paul
    Salloway, Stephen
    Apostolova, Liana G.
    Hansson, Oskar
    Ritchie, Craig
    Brooks, Dawn A.
    Mintun, Mark
    Skovronsky, Daniel M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (06): : 512 - 527
  • [4] TRAILBLAZER-ALZ 2: A Phase 3 Study to Assess Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
    Zimmer, Jennifer
    Solomon, Paul
    Evans, Cynthia D.
    Lu, Ming
    Sims, John R.
    Brooks, Dawn A.
    Mintun, Mark A.
    NEUROLOGY, 2022, 98 (18)
  • [5] Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials
    Zimmer, Jennifer A.
    Ardayfio, Paul
    Wang, Hong
    Khanna, Rashna
    Evans, Cynthia D.
    Lu, Ming
    Sparks, Jondavid
    Andersen, Scott
    Lauzon, Steve
    Nery, Emel Serap Monkul
    Battioui, Chakib
    Engle, Staci E.
    Biffi, Alessandro
    Svaldi, Diana
    Salloway, Stephen
    Greenberg, Steven M.
    Sperling, Reisa A.
    Mintun, Mark
    Brooks, Dawn A.
    Sims, John R.
    JAMA NEUROLOGY, 2025,
  • [6] Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial
    Sato, Shoichiro
    Hatakeyama, Naohisa
    Fujikoshi, Shinji
    Katayama, Sadao
    Katagiri, Hideaki
    Sims, John R.
    NEUROLOGY AND THERAPY, 2024, 13 (03) : 677 - 695
  • [7] Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial
    Pontecorvo, Michael J.
    Lu, Ming
    Burnham, Samantha C.
    Schade, Andrew E.
    Dage, Jeffrey L.
    Shcherbinin, Sergey
    Collins, Emily C.
    Sims, John R.
    Mintun, Mark A.
    JAMA NEUROLOGY, 2022, 79 (12) : 1250 - 1259
  • [8] Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
    Wessels, Alette M.
    Dennehy, Ellen B.
    Dowsett, Sherie A.
    Dickson, Samuel P.
    Hendrix, Suzanne B.
    NEUROLOGY-CLINICAL PRACTICE, 2023, 13 (02)
  • [9] Effects of ALZ-801, an Oral Amyloid Oligomer Inhibitor, on Biomarkers of Alzheimer's Disease (AD): 12-Month Results of Phase 2 Biomarker Study in Early AD
    Hey, John
    Abushakra, Susan
    Blennow, Kaj
    Scheltens, Philip
    Hort, Jakub
    Sheardova, Katerina
    Prins, Niels
    Rutgers, Sterre
    Dautzenberg, Paul
    Pazdera, Ladislav
    Kesslak, Patrick
    Mandelbaum, Rosalind
    Power, Aidan
    Tolar, Martin
    NEUROLOGY, 2023, 100 (17)
  • [10] APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials
    Evans, Cynthia D.
    Sparks, JonDavid
    Andersen, Scott W.
    Brooks, Dawn A.
    Hauck, Paula M.
    Mintun, Mark A.
    Sims, John R.
    ALZHEIMERS & DEMENTIA, 2023, 19 (12) : 5407 - 5417
12